deltatrials
Recruiting PHASE4 INTERVENTIONAL 1-arm NCT04657822

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Sponsor: Novartis Pharmaceuticals

Conditions Sickle Cell Disease
Interventions Crizanlizumab
Updated 27 times since 2021 Last updated: Oct 24, 2025 Started: Jun 10, 2021 Primary completion: Jun 10, 2031 Completion: Jun 10, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Sickle Cell Disease, this trial is actively recruiting participants. The trial is conducted by Novartis Pharmaceuticals and has accumulated 27 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Dec 2022 · 5 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jul 2025 · 2 months · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 10 months · monthly snapshot

Change History

27 versions recorded

  1. Nov 2025 — Present [monthly]

    Recruiting PHASE4

  2. Sep 2025 — Nov 2025 [monthly]

    Recruiting PHASE4

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE4

  4. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE4

  5. May 2025 — Jul 2025 [monthly]

    Recruiting PHASE4

▶ Show 22 earlier versions

  1. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE4

  2. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE4

  3. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE4

  4. Nov 2024 — Feb 2025 [monthly]

    Recruiting PHASE4

  5. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE4

  6. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE4

  7. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE4

  8. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE4

  9. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE4

  10. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE4

  11. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE4

  12. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE4

  13. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE4

  14. Jul 2022 — Dec 2022 [monthly]

    Recruiting PHASE4

  15. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE4

  16. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE4

  17. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE4

  18. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE4

  19. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE4

  20. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  21. Apr 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE4

  22. Jan 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Augusta, United States , Barcelona, Spain , Beirut, Lebanon , Birmingham, United States , Brussels, Belgium , Cali, Colombia , Créteil, France , Fort Worth, United States , Greenville, United States and 16 more locations